INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 18, 2025.
| Inovio Pharmaceuticals, Inc. | |
| By: | /s/ JACQUELINE E. SHEA |
| Jacqueline E. SheaPresident, Chief Executive Officer and Director (On Behalf of the Registrant) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacqueline E. Shea and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form 10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ JACQUELINE E. SHEA | President, Chief Executive Officer and Director (Principal Executive Officer) | March 18, 2025 |
| Jacqueline E. Shea | ||
| /s/ SIMON X. BENITO | Chairman of the Board of Directors | March 18, 2025 |
| Simon X. Benito | ||
| /s/ PETER KIES | Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer) | March 18, 2025 |
| Peter Kies | ||
| /s/ ROGER D. DANSEY | Director | March 18, 2025 |
| Roger D. Dansey | ||
| /s/ ANN C. MILLER | Director | March 18, 2025 |
| Ann C. Miller | ||
| /s/ JAY SHEPARD | Director | March 18, 2025 |
| Jay Shepard | ||
| /s/ DAVID B. WEINER | Director | March 18, 2025 |
| David B. Weiner | ||
| /s/ WENDY L. YARNO | Director | March 18, 2025 |
| Wendy L. Yarno | ||
| /s/ LOTA S. ZOTH | Director | March 18, 2025 |
| Lota S. Zoth | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.